CompletedNCT03247517
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
Researchers compared 200mg SPN-812, 400mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Medication studyAges 12–17United States
Understand this study
What did researchers investigate?
Researchers compared 200mg SPN-812, 400mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 12 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Dothan, United States · Orange, United States and 10 more locationsSee all locations and recruitment
- Activities
- Placebo comparator · Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: November 2, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 310
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT03247517
- Official title
Show the full official title
Evaluation of SPN 812 (Viloxazine Extended-release Capsule) 200 and 400 mg Efficacy and Safety in Adolescents With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
Recruitment & locations
CompletedDothan · Orange · Hialeah
9 more locations
- Jacksonville
- Miami
- Meridian
- New York
- Rochester
- Memphis
- Arlington
- Houston
- The Woodlands
Questions about this study
What did researchers investigate?
Researchers compared 200mg SPN-812, 400mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo, 200mg SPN-812 and 400mg SPN-812.
Who was this study for?
This study was for people with ADHD. Listed age limits: 12 years to 17 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)